HMGB1 enhances the migratory and invasive abilities of A2780/DDP cells by facilitating epithelial to mesenchymal transition via GSK‑3β

Wang,Jinhua; Zheng,Qiaomei; Zhao,Yanjing; Chen,Shaozhan; Chen,Lihong

doi:10.3892/etm.2024.12390

HMGB1 enhances the migratory and invasive abilities of A2780/DDP cells by facilitating epithelial to mesenchymal transition via GSK‑3β

Authors:
- Jinhua Wang
- Qiaomei Zheng
- Yanjing Zhao
- Shaozhan Chen
- Lihong Chen
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Fujian Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China, Department of Surgery, 92403 Military Hospital, Fuzhou, Fujian 350015, P.R. China
Published online on: January 15, 2024 https://doi.org/10.3892/etm.2024.12390
Article Number: 102
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the impact and mechanism of high mobility group box 1 (HMGB1) on the regulation of cell migration and invasion in A2780/DDP cisplatin‑resistant ovarian cancer cells. After transfecting small interfering (si)RNA‑HMGB1 into A2780/DDP cells, Transwell migration and invasion assays were conducted to assess alterations in the cell migratory and invasive abilities. Additionally, western blotting analyses were performed to examine changes in HMGB1, phosphorylated (p)‑GSK‑3β, GSK‑3β, E‑cadherin and vimentin expression levels. The results of the present study demonstrated that the migratory and invasive abilities of A2780/DDP cells were significantly higher compared with those of A2780 cells. Additionally, the expression levels of HMGB1, p‑GSK‑3β and the mesenchymal phenotype marker, vimentin, in A2780/DDP cells were significantly elevated relative to the levels in A2780 cells. Conversely, the expression level of the epithelial phenotype marker, E‑cadherin, was markedly decreased compared with that in A2780 cells. Following transfection of A2780/DDP cells with siRNA‑HMGB1, there was a significant reduction in the rate of cell migration and invasion. Simultaneously, the expression levels of HMGB1, p‑GSK‑3β and vimentin were downregulated while the level of E‑cadherin was upregulated. It was therefore concluded that the high expression of HMGB1 in A2780/DDP cells enhanced the cell migration and invasion abilities by facilitating epithelial to mesenchymal transition via GSK‑3β.

View Figures

View References

1	Havasi A, Cainap SS, Havasi AT and Cainap C: Ovarian cancer-insights into platinum resistance and overcoming it. Medicina (Kaunas). 59(544)2023.PubMed/NCBI View Article : Google Scholar
2	Lheureux S, Braunstein M and Oza AM: Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 69:280–304. 2019.PubMed/NCBI View Article : Google Scholar
3	Pignata S, C Cecere S, Du Bois A, Harter P and Heitz F: Treatment of recurrent ovarian cancer. Ann Oncol. 28 (suppl_8):viii51–viii56. 2017.PubMed/NCBI View Article : Google Scholar
4	Yang L, Xie HJ, Li YY, Wang X, Liu XX and Mai J: Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (Review). Oncol Rep. 47(82)2022.PubMed/NCBI View Article : Google Scholar
5	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
6	Arnaoutoglou C, Dampala K, Anthoulakis C, Papanikolaou EG, Tentas I, Dragoutsos G, Machairiotis N, Zarogoulidis P, Ioannidis A, Matthaios D, et al: Epithelial ovarian cancer: A five year review. Medicina (Kaunas). 59(1183)2023.PubMed/NCBI View Article : Google Scholar
7	Song M, Cui M and Liu K: Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem. 232(114205)2022.PubMed/NCBI View Article : Google Scholar
8	Goldberg JM, Piver MS, Hempling RE and Recio FO: Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol. 63:312–317. 1996.PubMed/NCBI View Article : Google Scholar
9	Ozols RF: Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer. Semin Oncol. 27 (3 Suppl 7):S3–S7. 2000.PubMed/NCBI
10	van Zyl B, Tang D and Bowden NA: Biomarkers of platinum resistance in ovarian cancer: What can we use to improve treatment. Endocr Relat Cancer. 25:R303–R318. 2018.PubMed/NCBI View Article : Google Scholar
11	Loret N, Denys H, Tummers P and Berx G: The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance. Cancers (Basel). 11(838)2019.PubMed/NCBI View Article : Google Scholar
12	Ahmed N, Abubaker K, Findlay J and Quinn M: Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets. 10:268–278. 2010.PubMed/NCBI View Article : Google Scholar
13	Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG and Bagnato A: Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 17:2350–2360. 2011.PubMed/NCBI View Article : Google Scholar
14	Cao L, Wan Q, Li F and Tang CE: MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep. 51:456–461. 2018.PubMed/NCBI View Article : Google Scholar
15	Liang F, Ren C, Wang J, Wang S, Yang L, Han X, Chen Y, Tong G and Yang G: The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy. Oncogenesis. 8(59)2019.PubMed/NCBI View Article : Google Scholar
16	Qiu Y, Chen Y, Zeng T, Guo W, Zhou W and Yang X: High-mobility group box-B1 (HMGB1) mediates the hypoxia-induced mesenchymal transition of osteoblast cells via activating ERK/JNK signaling. Cell Biol Int. 40:1152–1161. 2016.PubMed/NCBI View Article : Google Scholar
17	Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, Huang J, Yu Y, Fan XG, Yan Z, et al: HMGB1 in health and disease. Mol Aspects Med. 40:1–116. 2014.PubMed/NCBI View Article : Google Scholar
18	Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L and Tang D: HMGB1 promotes drug resistance in osteosarcoma. Cancer Res. 72:230–238. 2012.PubMed/NCBI View Article : Google Scholar
19	Zheng H, Chen JN, Yu X, Jiang P, Yuan L, Shen HS, Zhao LH, Chen PF and Yang M: HMGB1 enhances drug resistance and promotes in vivo tumor growth of lung cancer cells. DNA Cell Biol. 35:622–627. 2016.PubMed/NCBI View Article : Google Scholar
20	Li S and Wei Y: Association of HMGB1, BRCA1 and P62 expression in ovarian cancer and chemotherapy sensitivity. Oncol Lett. 15:9572–9576. 2018.PubMed/NCBI View Article : Google Scholar
21	Shu W: Downregulation of high mobility group protein box-1 resensitizes ovarian cancer cells to carboplatin. Oncol Lett. 16:4586–4592. 2018.PubMed/NCBI View Article : Google Scholar
22	Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, et al: HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 6(e10)2009.PubMed/NCBI View Article : Google Scholar
23	Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, Muhammad AK, Puntel M, Kroeger KM, Liu C, Lee S, et al: Release of HMGB1 in response to proapoptotic glioma killing strategies: Efficacy and neurotoxicity. Clin Cancer Res. 15:4401–4414. 2009.PubMed/NCBI View Article : Google Scholar
24	Chen Y, Cai L, Guo X, Li Z, Liao X, Zhang X, Huang L and He J: HMGB1-activated fibroblasts promote breast cancer cells metastasis via RAGE/aerobic glycolysis. Neoplasma. 68:71–78. 2021.PubMed/NCBI View Article : Google Scholar
25	Li H, Li J, Zhang G, Da Q, Chen L, Yu S, Zhou Q, Weng Z, Xin Z, Shi L, et al: HMGB1-Induced p62 overexpression promotes snail-mediated epithelial-mesenchymal transition in glioblastoma cells via the degradation of GSK-3β. Theranostics. 9:1909–1922. 2019.PubMed/NCBI View Article : Google Scholar
26	Zhang Y, Ren H, Li J, Xue R, Liu H, Zhu Z, Pan C, Lin Y, Hu A, Gou P, et al: Elevated HMGB1 expression induced by hepatitis B virus X protein promotes epithelial-mesenchymal transition and angiogenesis through STAT3/miR-34a/NF-κB in primary liver cancer. Am J Cancer Res. 11:479–494. 2021.PubMed/NCBI
27	Chen J, Liu X, Zhang J and Zhao Y: Targeting HMGB1 inhibits ovarian cancer growth and metastasis by lentivirus-mediated RNA interference. J Cell Physiol. 227:3629–3638. 2012.PubMed/NCBI View Article : Google Scholar
28	Zheng Q, Xu Y, Lu J, Zhao J, Wei X and Liu P: Emodin Inhibits Migration and Invasion of Human Endometrial Stromal Cells by Facilitating the Mesenchymal-Epithelial Transition Through Targeting ILK. Reprod Sci. 23:1526–1535. 2016.PubMed/NCBI View Article : Google Scholar
29	Yeung KT and Yang J: Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 11:28–39. 2017.PubMed/NCBI View Article : Google Scholar
30	Mittal V: Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 13:395–412. 2018.PubMed/NCBI View Article : Google Scholar
31	Li L, Li P, Zhang W, Zhou H, Guo E, Hu G and Zhang L: FERMT1 contributes to the migration and invasion of nasopharyngeal carcinoma through epithelial-mesenchymal transition and cell cycle arrest. Cancer Cell Int. 22(70)2022.PubMed/NCBI View Article : Google Scholar
32	Cui X, Wang Y, Lan W, Wang S, Cui Y, Zhang X, Lin Z and Piao J: SPOCK1 promotes metastasis in pancreatic cancer via NF-κB-dependent epithelial-mesenchymal transition by interacting with IκB-α. Cell Oncol (Dordr). 45:69–84. 2022.PubMed/NCBI View Article : Google Scholar
33	Liang H, Yu T, Han Y, Jiang H, Wang C, You T, Zhao X, Shan H, Yang R, Yang L, et al: LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Cancer. 17(119)2018.PubMed/NCBI View Article : Google Scholar
34	Kim LK, Park SA, Yang Y, Kim YT, Heo TH and Kim HJ: LncRNA SRA mediates cell migration, invasion, and progression of ovarian cancer via NOTCH signaling and epithelial-mesenchymal transition. Biosci Rep. 41(BSR20210565)2021.PubMed/NCBI View Article : Google Scholar
35	He H, Wang X, Chen J, Sun L, Sun H and Xie K: High-Mobility Group Box 1 (HMGB1) promotes angiogenesis and tumor migration by regulating hypoxia-inducible factor 1 (HIF-1α) expression via the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway in breast cancer cells. Med Sci Monit. 25:2352–2360. 2019.PubMed/NCBI View Article : Google Scholar
36	van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA and Griffioen AW: Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene. 32:363–374. 2013.PubMed/NCBI View Article : Google Scholar
37	Chung HW, Jang S, Kim H and Lim JB: Combined targeting of high-mobility group box-1 and interleukin-8 to control micrometastasis potential in gastric cancer. Int J Cancer. 137:1598–1609. 2015.PubMed/NCBI View Article : Google Scholar
38	Liu PL, Liu WL, Chang JM, Chen YH, Liu YP, Kuo HF, Hsieh CC, Ding YS, Chen WW and Chong IW: MicroRNA-200c inhibits epithelial-mesenchymal transition, invasion, and migration of lung cancer by targeting HMGB1. PLoS One. 12(e0180844)2017.PubMed/NCBI View Article : Google Scholar
39	Li Y, Tian J, Fu X, Chen Y, Zhang W, Yao H and Hao Q: Serum high mobility group box protein 1 as a clinical marker for ovarian cancer. Neoplasma. 61:579–584. 2014.PubMed/NCBI View Article : Google Scholar
40	Paek J, Lee M, Nam EJ, Kim SW and Kim YT: Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer. Arch Gynecol Obstet. 293:645–650. 2016.PubMed/NCBI View Article : Google Scholar
41	Jiang W, Jiang P, Yang R and Liu DF: Functional role of SIRT1-induced HMGB1 expression and acetylation in migration, invasion and angiogenesis of ovarian cancer. Eur Rev Med Pharmacol Sci. 22:4431–4439. 2018.PubMed/NCBI View Article : Google Scholar